

## Minutes

Date Wednesday, 04/09/2024

Time 9:00 AM

To Committee Members

At [REDACTED]

Subject AWERB 3Rs Committee

Our Ref Doc.AWERB.3Rs.04.09.24

**AWERB 3Rs Committee :** [REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]

**In Attendance:** [REDACTED]  
[REDACTED]  
[REDACTED]

**Minutes –** [REDACTED]

**Apologies:** [REDACTED]  
[REDACTED]

### 1. Minutes

The minutes from the previous meeting held on 07/08/2024 were approved.

### 2. Matters arising

There were no matters arising from the meeting held on 07/08/2024.

### 3. Retrospective Reviews / Retrospective Assessments

**(a)** [REDACTED] - Neural regulation of fertility – RR

The committee discussed the following:

- Further explanation needed regarding severities in Section 2.2.
- Clarification needed in Section 2.7 regarding wastage associated with the type of research conducted.
- Details of refinements need to be highlighted in Section 4.8.
- Further clarification needed in Section 4.9 about why external engagement could not be supported.
- Further information about how breeding issues are being addressed in Section 5.5.

**(b)** [REDACTED] - Investigating the efficacy and potential of a novel delivery system to transfer materials across the blood-brain barrier – RR

The committee discussed the following:

- Further detail needed in Section 2.4 regarding the scientific endpoints of some animals.

- Further information needed in Section 2.9.
- Clarification needed regarding the publication in Section 3.5.
- A review of the date provided in Section 4.4.
- Further detailed needed in Section 4.5 regarding the replacement and refinement.

**(c)** [REDACTED] - Stem cell mechanisms for lung development and regeneration – RR

The committee discuss the following:

- Further detail needed in Section 3.1 regarding the reason for not writing a new PPL.
- Consideration needed regarding whether information in Section 3.1, should also be included in Section 3.2.
- The outputs listed in Section 3.11 to be moved to 4.8.

**(d)** [REDACTED] - Potent monoclonal antibodies for biologics discovery - RR

The committee discussed the following:

- Answer to be amended in Section 1.
- The final part of the table in Section 2.1 to be removed.
- The percentages quoted in Section 2.3 to be reviewed.
- Consideration to be given to whether the use of different species in Section 3.7 is a refinement
- Further detail needed in Section 4.9 regarding why the sharing of techniques has not been possible.

#### **4. Project Licence Applications – New / Amendments**

**(a)** [REDACTED] - Tuberculosis pathogenesis and treatment in zebrafish and medaka –  
New

The committee discussed the following:

- A review of protocol 5, step 2 needed.
- A review of the severity and reasoning in protocol 5, step 3 needed.
- A review of procedures listed in protocol 5, step 6 needed.

#### **5. Standard Condition 18 Reports**

There has been a noticeable reduction in reports. In June and July incidents have been low. There were 21 SC18 reports in July. This affected 24 animals in total. 19 of those animals were found dead for unknown reasons.

#### **6. 3Rs information/reports**

[REDACTED] discussed the Dosing Guides for Common Veterinary Drugs for mice. These have been updated to make these more user friendly and doses amended to reflect current best practice. Once this guidance has been approved for mice the guide will be looked at to make it relevant for rats. [REDACTED] commented that the solution for injection text could become confusing and asked if this could be edited to make it clearer. [REDACTED] suggested having some information about rounding up and rounding down to make the dosing amounts clearer for users.

#### **7. Minutes of the AOC meeting.**

There were no approved minutes available for this meeting.

#### **8. Minutes of the AWERB Standing meeting**

There were no approved minutes available for this meeting.

**9. Any Other Business**

There was no other business to discuss.

**Date of next meeting:**

Wednesday 2<sup>nd</sup> October 2024 via MS Teams. [REDACTED] will chair the next meeting.